Candesartan in the prevention of cardiovascular catastrophes: emphasis on the pre-vention of stroke
Аннотация
Об авторах
О. М. ДрапкинаРоссия
О. Н. Дикур
Россия
Список литературы
1. WHO atlas of heart disease and stroke. http://www.who.int/cardiovascular_diseases/en/cvd_atlas_ 15_burden_stroke.pdf. Accessed July 8, 2009.
2. Meairs S, Wahlgren N, Dirnagl U et al. Stroke research priorities for the next decade - a representative view of the European scientific community. Cerebrovasc Dis 2006; 22 (2-3): 75-82.
3. Драпкина О.М., Ашихмин Я.И., Ивашкин В.Т. Профилактика инсульта. Рос. мед. вести. 2007; 4: 60-75.
4. Neal B, MacMahon S. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
5. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355 (9215): 1575-81.
6. Boutitie F, Oprisiu R, Achard JM et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens 2007; 25 (8): 1543-53.
7. Kozak A, Ergul A, El-Remessy AB et al. Candesartan Augments Ischemia-Induced Proangiogenic State and Results in Sustained Improvement After Stroke. Stroke 2009; 40: 1870-6.
8. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000; 34: 526.
9. Драпкина О.М., Дикур О.Н. Преимущество антагонистов рецепторов ангиотензина II в лечении АГ у женщин. Рус. мед. журн. 2008; 16 (21): 1462-5.
10. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left. ventricular systolic function intolerant to angiotensin.converting.enzyme inhibitors: the CHARM. Alternative trial. Lancet 2003; 362: 772-6.
11. Мареев В.Ю., Агеев Ф.Т. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (2-й пересмотр). Сердечн. недостат. 2006; 8 (2).
12. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left. ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003; 362: 777-81.
13. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-74.
14. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-300.
15. Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761-9.
16. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Eldery (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
17. Schrader J, Luders S, Kollmann K et al. The ACCESS Study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-703.
18. Neyer J et al. A report from the American Heart Association Statistics Commettee and Stroke Statistics Subcommettee. Circulation 2007; 115: e69-171.
19. Kasanuki H. et al European Heart Journal (2009)30, 1203-12.
Рецензия
Для цитирования:
Драпкина О.М., Дикур О.Н. . Системные гипертензии. 2009;(4):66-69.
For citation:
, Candesartan in the prevention of cardiovascular catastrophes: emphasis on the pre-vention of stroke. Systemic Hypertension. 2009;(4):66-69.
Послать статью по эл. почте 